Accelerating small molecule discovery chemistry by optimizing your Design-Make-Test-Analyze workflow

Coordinating new molecule chemistry through the DMTA cycle has never been more important or more challenging. See how Torx™ uses DMTA as a guide to manage small molecule chemistry projects to a successful outcome whatever the business model adopted.

Coordinating new molecule chemistry through the Design-Make-Test-Analyze (DMTA) cycle has never been more important or more challenging. Each project in pharmaceutical and biotechnology companies can adopt a wide range of strategies such as fragment-based, ligand-based, or structure-based approaches to prosecute candidates for their targets. Combined with these are varied business models which see compounds synthesized across a wide range of geographies and organizations - a situation that has been amplified under COVID-19 induced lockdowns. These effects mean the DMTA cycle is the one common process throughout the majority of projects so it is under pressure to deliver more efficiency at a time when processes naturally segment information.

Torx™ uses DMTA as a guide to manage small molecule chemistry projects to a successful outcome whatever the business model adopted. It provides a central platform for coordination of team work, dissemination of information, and knowledge capture. In this webinar, delivered at the Cresset User Group Meeting, we demonstrate the fundamental principles of Torx and describe Torx Design and Torx Make in detail, showing how they enable users to take control of their drug discovery process.

If you'd like to explore how Torx can put you on the path to faster quality candidate selection and new IP, contact us to request an evaluation.